Only A Third Of Patients With Advanced Cancer Had Molecular Testing To Help Guide Use Of Targeted Therapies, Review Shows

MedPage Today (7/11, Bankhead) reported, “Only a third of patients with advanced cancer had molecular testing to help guide the use of targeted therapies, a review of 26,000 patients showed.” Investigators found that “overall, 35% of patients’ records had evidence of comprehensive genomic profiling.” Data indicated that “the rate increased modestly from 32% at the beginning of the study period to 39% at the end.” Investigators found that “among tested patients, those with colorectal cancer and non-small cell lung cancer were more likely to receive targeted therapy.” The findings were published in JAMA Network Open.